COMPANY RESEARCHOrum Therapeutics, Inc.
Orum Therapeutics is a South Korean biotechnology company developing targeted therapeutic approaches that combine antibody delivery with protein degradation technologies. Its company FAQ describes degrader-antibody conjugates and a platform intended for treatment of cancers, including hematologic malignancies. The same official source identifies its KOSDAQ listing under 475830. This directory captures a stable issuer identity, scientific platform and disease classification; the current clinical portfolio and experimental results should instead be checked against original company announcements and regulatory records. Listing status remains subject to subsequent exchange updates.
Company at a glance
Corporate information
- Company entity
- Orum Therapeutics, Inc.
- Headquarters / principal office
- South Korea
- Founded
- Not verified
- Ownership / capital status
- Publicly tradedPublicly listed
- Official corporate reference
- https://www.orumrx.com
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-08 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
KOSDAQ: 475830
antibody-degrader-conjugates · targeted-protein-degradation · antibodies
oncology · hematologic-cancers
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Orum Therapeutics is a South Korean biotechnology company developing targeted therapeutic approaches that combine antibody delivery with protein degradation technologies. Its company FAQ describes degrader-antibody conjugates and a platform intended for treatment of cancers, including hematologic malignancies. The same official source identifies its KOSDAQ listing under 475830. This directory captures a stable issuer identity, scientific platform and disease classification; the current clinical portfolio and experimental results should instead be checked against original company announcements and regulatory records. Listing status remains subject to subsequent exchange updates.
Business, technology & evidence
- SecuritiesKOSDAQ: 475830
Individual program detail is not recorded. Consult the original sources below.
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 0 / 0 related items
No cataloged update explicitly mentions this company.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinSources & open questions
- Official issuer and R&D disclosure · Orum Therapeutics, Inc. ↗Orum Therapeutics, Inc. ·
Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.